trial

A Food Effect Study of LY03020 in Healthy Subjects

NCTId NCT07292233
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Active Not Recruiting
Enrollment 16 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2025-08-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Active Not Recruiting
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2025-07-30
Primary completion
2025-08-27
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
LY03020

Sponsors

Luye Pharma Group Ltd.Lead Sponsor

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE1
Primary Completion Date
2025-08-27
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
LY03020
drug
lead_sponsor
Luye Pharma Group Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Alzheimer's Disease Psychosis
indication